Published on 11 May 2022 on Simply Wall St. via Yahoo Finance

Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Shift From Loss To Profit

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. With the latest financial year loss of US$25m and a trailing-twelve-month loss of US$26m, the US$149m market-cap company amplified its loss by moving further away from its breakeven target. As path to profitability is the topic on Citius Pharmaceuticals' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

See our latest analysis for Citius Pharmaceuticals

Consensus from 3 of the American Pharmaceuticals analysts is that Citius Pharmaceuticals is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$16m in 2024. The company is therefore projected to breakeven around 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2024? Working backwards from analyst estimates, it turns out that they expect the company to grow 75% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.